

Multiple Sclerosis Therapeutics Market - 2024-2033

<https://marketpublishers.com/r/M1FDB980BB0FEN.html>

Date: February 2026

Pages: 210

Price: US\$ 2,999.00 (Single User License)

ID: M1FDB980BB0FEN

Abstracts

The Multiple Sclerosis Therapeutics Market was valued at US\$ 27.42 Billion in 2024 and is anticipated to reach US\$ 46.22 Billion by 2033, at a CAGR of 0.061 from 2026 to 2032.

The report delivers in-depth insights into key market dynamics, including regional growth trends, market segmentation, CAGR projections, and the revenue performance of leading industry players. It also highlights major growth drivers shaping the market landscape. Designed to provide a clear and comprehensive perspective, the report offers a detailed view of the current market size in terms of both value and volume, along with emerging opportunities and the overall development outlook of the Multiple Sclerosis Therapeutics Market.

This report delivers a comprehensive overview of the Multiple Sclerosis Therapeutics Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Multiple Sclerosis Therapeutics Market. The Multiple Sclerosis Therapeutics Market size, estimates, and forecasts are provided in terms of output/shipments (K MT) and revenue (US\$ millions), with 2025 as the base year and historical and forecast data for 2024–2033.

Multiple Sclerosis Therapeutics Market Scope:

By Disease Type

Relapsing-Remitting MS (RRMS)

Secondary-Progressive MS (SPMS)

Primary-Progressive MS (PPMS)

Clinically Isolated Syndrome

By Drug Class

Disease-Modifying Therapies (DMTs)

Corticosteroids

Monoclonal Antibodies

Others

By Route of Administration

Oral

Injectable

By Distribution Channel

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

By Regional Market Analysis and Growth Opportunities

North America

Europe

Asia-Pacific

South America

Key Players

Biogen

Merck KGaA

Genentech USA, Inc.

Novartis AG

Bristol-Myers Squibb Company

Genzyme Corporation (Sanofi)

Teva Pharmaceuticals USA, Inc.

TG Therapeutics, Inc.

Vanda Pharmaceuticals, Inc.

Cycle Pharmaceuticals Limited

Major Highlights

This report delivers a comprehensive overview of the Multiple Sclerosis Therapeutics Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Multiple Sclerosis Therapeutics Market. The Multiple Sclerosis Therapeutics Market size, estimates, and forecasts are provided in terms of output/shipments (K Sqm) and revenue (US\$ millions), with 2025 as the base year and historical and forecast data for 2024–2033.

This report will assist keyword manufacturers, new entrants, and companies across the industry value chain with information on revenues, production, and average prices for

the overall market and its sub-segments, by company, by Type, by Application, and by region.

Regional Analysis:

North America (U.S., Canada, Mexico)

Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

South America (Colombia, Brazil, Argentina, Rest of South America)

Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Partner Identification

Increase Your Customer Base by 3X using our Partner Identification tool

Uncover strategic collaboration opportunities with DataM vetted partners aligned to your ecosystem.

Identify high potential M&A targets based on synergies, market positioning and growth trajectory.

Prioritize partners by strategic fit rather than general capability.

Why Choose DataM?

Data-Driven Insights: Dive into detailed analyses with granular insights such as pricing, market shares and value chain evaluations, enriched by interviews with industry leaders and disruptors.

Post-Purchase Support and Expert Analyst Consultations: As a valued client,

gain direct access to our expert analysts for personalized advice and strategic guidance, tailored to your specific needs and challenges.

White Papers and Case Studies: Benefit quarterly from our in-depth studies related to your purchased titles, tailored to refine your operational and marketing strategies for maximum impact.

Annual Updates on Purchased Reports: As an existing customer, enjoy the privilege of annual updates to your reports, ensuring you stay abreast of the latest market insights and technological advancements. Terms and conditions apply.

Specialized Focus on Emerging Markets: DataM differentiates itself by delivering in-depth, specialized insights specifically for emerging markets, rather than offering generalized geographic overviews. This approach equips our clients with a nuanced understanding and actionable intelligence that are essential for navigating and succeeding in high-growth regions.

Value of DataM Reports: Our reports offer specialized insights tailored to the latest trends and specific business inquiries. This personalized approach provides a deeper, strategic perspective, ensuring you receive the precise information necessary to make informed decisions. These insights complement and go beyond what is typically available in generic databases.

Target Audience 2026

Manufacturers/ Buyers

Industry Investors/Investment Bankers

Research Professionals

Emerging Companies

Contents

1. MARKET INTRODUCTION AND SCOPE

- 1.1. Objectives of the Report
- 1.2. Report Coverage & Definitions
- 1.3. Report Scope

2. EXECUTIVE INSIGHTS AND KEY TAKEAWAYS

- 2.1. Market Highlights and Strategic Takeaways
- 2.2. Key Trends and Future Projections
- 2.3. Snippet by Disease Type
- 2.4. Snippet by Drug Class
- 2.5. Snippet by Route of Administration
- 2.6. Snippet by Distribution Channel
- 2.7. Snippet by Region

3. DYNAMICS

- 3.1. Impacting Factors
 - 3.1.1. Drivers
 - 3.1.1.1. Rising Prevalence of Multiple Sclerosis
 - 3.1.1.2. Advancements in Disease-Modifying Therapies
 - 3.1.2. Restraints
 - 3.1.2.1. High Cost of Treatment
 - 3.1.2.2. Safety Concerns and Adverse Effects
 - 3.1.3. Opportunity
 - 3.1.3.1. Expansion into Progressive MS Treatment
 - 3.1.3.2. Development of Next-Generation Oral and Long-Acting Formulations
 - 3.1.4. Impact Analysis

4. STRATEGIC INSIGHTS AND INDUSTRY OUTLOOK

- 4.1. Market Leaders and Pioneers
 - 4.1.1. Emerging Pioneers and Prominent Players
 - 4.1.2. Established Leaders with the Largest Marketing Brand
 - 4.1.3. Market Leaders with Established Products
- 4.2. Latest Developments and Breakthroughs

- 4.3. Regulatory and Reimbursement Landscape
 - 4.3.1. North America
 - 4.3.2. Europe
 - 4.3.3. Asia Pacific
 - 4.3.4. South America
 - 4.3.5. Middle East & Africa
- 4.4. Porter's Five Forces Analysis
 - 4.4.1. Threat of New Entrants
 - 4.4.2. Threat of Substitutes
 - 4.4.3. Bargaining Power of Suppliers
 - 4.4.4. Bargaining Power of Buyers
 - 4.4.5. Intensity of Competitive Rivalry
- 4.5. Supply Chain Analysis
 - 4.5.1. Raw material Suppliers
 - 4.5.2. Manufacturers
 - 4.5.3. Regulatory Approvals/Certifications
 - 4.5.4. Distributors
 - 4.5.5. End-Users
- 4.6. Pipeline Analysis
- 4.7. Patent Analysis
- 4.8. Unmet Needs and Gaps
- 4.9. Recommended Strategies for Market Entry and Expansion
- 4.10. Pricing Analysis and Price Dynamics

5. BY DISEASE TYPE

- 5.1. Introduction
 - 5.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
 - 5.1.2. Market Attractiveness Index, By Disease Type
- 5.2. Relapsing-Remitting MS (RRMS)*
 - 5.2.1. Introduction
 - 5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 5.3. Secondary-Progressive MS (SPMS)
- 5.4. Primary-Progressive MS (PPMS)
- 5.5. Clinically Isolated Syndrome

6. BY DRUG CLASS

- 6.1. Introduction

- 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
- 6.1.2. Market Attractiveness Index, By Drug Class
- 6.2. Disease-Modifying Therapies (DMTs)*
 - 6.2.1. Introduction
 - 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 6.3. Corticosteroids
- 6.4. Monoclonal Antibodies
- 6.5. Others

7. BY ROUTE OF ADMINISTRATION

- 7.1. Introduction
 - 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
 - 7.1.2. Market Attractiveness Index, By Route of Administration
- 7.2. Oral*
 - 7.2.1. Introduction
 - 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 7.3. Injectable

8. BY DISTRIBUTION CHANNEL

- 8.1. Introduction
 - 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
 - 8.1.2. Market Attractiveness Index, By Distribution Channel
- 8.2. Hospital Pharmacies*
 - 8.2.1. Introduction
 - 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 8.3. Retail Pharmacies
- 8.4. Online Pharmacies

9. BY REGIONAL MARKET ANALYSIS AND GROWTH OPPORTUNITIES

- 9.1. Introduction
 - 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
 - 9.1.2. Market Attractiveness Index, By Region
- 9.2. North America
 - 9.2.1. Introduction
 - 9.2.2. Key Region-Specific Dynamics

9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type

9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class

9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of

Administration

9.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

9.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country

9.2.7.1. U.S.

9.2.7.2. Canada

9.2.7.3. Mexico

9.3. Europe

9.3.1. Introduction

9.3.2. Key Region-Specific Dynamics

9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type

9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class

9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of

Administration

9.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

9.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country

9.3.7.1. Germany

9.3.7.2. UK

9.3.7.3. France

9.3.7.4. Spain

9.3.7.5. Italy

9.3.7.6. Rest of Europe

9.4. Asia-Pacific

9.4.1. Introduction

9.4.2. Key Region-Specific Dynamics

9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type

9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class

9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of

Administration

9.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

9.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country

9.4.7.1. China

9.4.7.2. India

9.4.7.3. Japan

9.4.7.4. South Korea

9.4.7.5. Rest of Asia-Pacific

9.5. South America

- 9.5.1. Introduction
- 9.5.2. Key Region-Specific Dynamics
- 9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
- 9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
- 9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
- 9.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
- 9.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
 - 9.5.7.1. Brazil
 - 9.5.7.2. Argentina
 - 9.5.7.3. Rest of South America
- 9.5.8. Middle East and Africa
 - 9.5.8.1. Introduction
 - 9.5.8.2. Key Region-Specific Dynamics
 - 9.5.8.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
 - 9.5.8.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
 - 9.5.8.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
 - 9.5.8.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

10. COMPETITIVE LANDSCAPE AND MARKET POSITIONING

- 10.1. Competitive Overview and Key Market Players
- 10.2. Market Share Analysis and Positioning Matrix
- 10.3. Strategic Partnerships, Mergers & Acquisitions
- 10.4. Key Developments in Product Portfolios and Innovations
- 10.5. Company Benchmarking

11. COMPANY PROFILES

- 11.1. Biogen*
 - 11.1.1. Company Overview
 - 11.1.2. Product Portfolio
 - 11.1.2.1. Product Description
 - 11.1.2.2. Product Key Performance Indicators (KPIs)
 - 11.1.3. Financial Overview
 - 11.1.3.1. Company Revenue
 - 11.1.3.2. Geographical Revenue Shares

- 11.1.3.3. Revenue Forecasts
- 11.1.4. Key Developments
 - 11.1.4.1. Mergers & Acquisitions
 - 11.1.4.2. Key Product Development Activities
 - 11.1.4.3. Regulatory Approvals, etc.
 - 11.1.4.4. SWOT Analysis
- 11.2. Merck KGaA
- 11.3. Genentech USA, Inc.
- 11.4. Novartis AG
- 11.5. Bristol-Myers Squibb Company
- 11.6. Genzyme Corporation (Sanofi)
- 11.7. Teva Pharmaceuticals USA, Inc.
- 11.8. TG Therapeutics, Inc.
- 11.9. Vanda Pharmaceuticals, Inc.
- 11.10. Cycle Pharmaceuticals Limited (LIST NOT EXHAUSTIVE)

12. ASSUMPTIONS AND RESEARCH METHODOLOGY

- 12.1. Data Collection Methods
- 12.2. Data Triangulation
- 12.3. Forecasting Techniques
- 12.4. Data Verification and Validation

13. APPENDIX

- 13.1. About Us and Services
- 13.2. Contact Us

I would like to order

Product name: Multiple Sclerosis Therapeutics Market - 2024-2033

Product link: <https://marketpublishers.com/r/M1FDB980BB0FEN.html>

Price: US\$ 2,999.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/M1FDB980BB0FEN.html>